Page 31 - SRPSKO DRUŠTVO ISTRAŽIVAČA RAKA
P. 31
SDIRSACR Oncology Insights
To enable translational use of EVs as biomarkers, multiple platforms have been developed for their isolation and
capture. These methods vary in throughput, specificity, and downstream compatibility, and are at different levels of
clinical readiness (36, 37). A comparative overview of key platforms is provided in Table 2, highlighting their capture
principles, analytical potential, and performance notes derived from recent clinical and preclinical studies (12, 22, 23,
31, 38, 39).
Table 2. Comparison of EV isolation and capture platforms relevant for clinical translation.
16
